BIOTRICITY INC. (OTCMKTS:BTCY) Files An 8-K Unregistered Sales of Equity SecuritiesItem 3.02.
Unregistered Sales of Equity Securities.
From November 15, 2017 through January 24, 2018, Biotricity Inc. (“the Registrant”) issued an aggregate of 127,400 shares of the Registrant’s common stock to consultants, advisors, and other services providers as consideration for services. The issuance of the 127,400 shares of common stock was exempt from registration under Section 4(a)(2) under the Securities Act of 1933, as amended and the rules promulgated thereunder (the “Securities Act”), as a transaction not involving a public offering, as the issuance thereof was made to a limited number of persons or entities as compensation for services rendered.
From November 15, 2017 through January 24, 2018, holders of exchangeable shares of the Company’s indirect subsidiary (the “Exchangeable Shares”) converted an aggregate of 679,858 Exchangeable Shares for an aggregate of 679,858 shares of the Registrant’s common stock. to the terms of conversion of the Exchangeable Shares, each such share is convertible, upon request and for no additional consideration, into 1 share of the common stock of the Registrant. The issuance of the 679,858 shares of common stock were exempt from registration under Section 4(a)(2) under the Securities Act as transactions not involving a public offering.
From November 15, 2017 through January 24, 2018, the Registrant issued an aggregate of 140,000 shares of the Registrant’s common stock in connection with the exercise of warrants previously issued to consultants as consideration for services. The issuance of the 140,000 shares of common stock was exempt from registration under Section 4(a)(2) under the Securities Act as a transaction not involving a public offering, as the issuance thereof was made to a limited number of persons or entities as compensation for services rendered, and/or 3(a)(9) under the Securities Act as the warrants were exercised for common stock by existing security holders and no commission or other remuneration was paid.
From November 15, 2017 through January 24, 2018, the Registrant issued an aggregate of 171,593 shares of the Registrant’s common stock in connection with the cashless exercise of warrants previously issued to brokers who assisted the Registrant in arranging funding. The issuance of the 171,593 shares of common stock was exempt from registration under Section 4(a)(2) under the Securities Act as a transaction not involving a public offering, as the issuance thereof was made to a limited number of persons or entities as compensation for services rendered, and/or 3(a)(9) under the Securities Act as the warrants were exercised for common stock by existing security holders and no commission or other remuneration was paid.
About BIOTRICITY INC. (OTCMKTS:BTCY)
Biotricity Inc is a Canada-based medical technology company. The Company delivers remote biometric monitoring solutions, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. It offers bioflux, an Electrocardiogram (ECG) monitoring system that enables physicians to diagnose cardiovascular diseases or coronary heart diseases, acts as an ambulatory monitor that detects arrhythmias, performs remote mobile cardiac telemetry diagnostic monitoring, and transmits ECG data via a built-in cellular radio in real time. The Company also provides biolife, a health and lifestyle solution for individuals, which consists of a device that monitors heart-rhythm or ECG, as well as respiration, calories, temperature, physical activity, and other.
